Methadone medical maintenance in primary care. An implementation evaluation

Department of Pharmacy, University of Washington Seattle, Seattle, Washington, United States
Journal of General Internal Medicine (Impact Factor: 3.42). 05/2005; 20(4):344-9. DOI: 10.1111/j.1525-1497.2005.04028.x
Source: PubMed


Methadone is effective treatment for opioid addiction, but regulations restrict its use. Methadone medical maintenance treats stabilized methadone patients in a medical setting, but only experimental programs have been studied.
To evaluate the implementation of the first methadone medical maintenance program established outside a research setting.
One-year program evaluation.
A public hospital and a community opioid treatment program.
Methadone patients with >1 year of clinical stability. Eleven generalist physicians and 4 hospital pharmacists.
Regulatory exemptions were requested. Physicians and pharmacists were trained. Patients were transferred to the medical setting and permitted 1-month supplies of methadone.
Patient eligibility and willingness to enroll, treatment retention, urine toxicology results, change in addiction severity and functional status, medical services provided, patient and physician satisfaction, and physician attitudes toward methadone maintenance.
Regulatory exemptions were obtained after a 14-month process, and the program was cited in federal policy as acceptable for widespread implementation. Forty-nine of 684 patients (7.2%) met stability criteria, and 30 enrolled. Twenty-eight were retained for 1 year, and 2 transferred to other programs. Two patients had opioid-positive urine tests and were managed in the medical setting. Previously unmet medical needs were addressed, and the Addiction Severity Index (ASI) medical composite score improved over time (P=.02). Patient and physician satisfaction were high, and physician attitudes toward methadone maintenance treatment became more positive (P=.007).
Methadone medical maintenance is complex to arrange but feasible outside a research setting, and can result in good clinical outcomes.

Download full-text


Available from: Dennis Donovan
  • Source
    • "The MMM (medical methadone maintenance) program in US (Merrill et al., 2005) during early 1980's showed very high success rate (around 70% retention rate), when it was integrated with primary care. However, safety concerns resulted in termination of this program (Merrill et al., 2005). MMT integrated with primary care, has been in place in Germany (Wittchen et al., 2008), with high retention rate (around 80%) compared to those in BC, Canada (around 60% (Nosyk, Marsh, Sun, Schechter, & Anis, 2010)). "
    [Show abstract] [Hide abstract]
    ABSTRACT: We described the changing characteristics and comorbidity levels of new patients into Methadone maintenance treatment (MMT) program in British Columbia, Canada, during its expansion period of 1998-2006. Analyses used administrative data. Generalized regression models were applied using Charlson Comorbidity Index (CCI) and Chronic Disease Score (CDS) as outcomes. 12,615 individuals initiated MMT during 1998-2006, while their odds of having moderate CCI (1 ≤ CCI ≤ 4) and mean CDS increased by 60% and 11%, respectively, after adjusting for confounders. MMT entrants were presented with progressively higher levels of comorbidity, independent of other characteristics. Future MMT policies should address higher levels of comorbidity among new patients.
    Full-text · Article · Jun 2013 · Substance Use & Misuse
  • Source
    • "Drug Crime 2004). Opioid substitution therapy has typically been administered in specialty clinics; however, primary care and outpatient settings may also be used for successful implementation of opioid substitution (Krantz & Mehler 2004, Merrill et al. 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Harm reduction is a pragmatic approach to reduce the harmful consequences of alcohol and drug use or other high-risk activities by incorporating several strategies that cut across the spectrum from safer use to managed use to abstinence. The primary goal of most harm-reduction approaches is to meet individuals "where they are at" and not to ignore or condemn the harmful behaviors but rather to work with the individual or community to minimize the harmful effects of a given behavior. The current review addresses some of the newest developments with respect to harm-reduction policy, prevention, and treatment. In particular, this review highlights policies and programs that have been evaluated in peer-reviewed journals and shown to be effective at reducing the harms associated with alcohol and drug use. The overall goal of this review is to present some of the most recent developments in the field of harm reduction.
    Full-text · Article · Mar 2010 · Annual Review of Clinical Psychology
  • Source
    • "Similar to nicotine replacement, opioid substitution therapies have been developed for drugs such as heroin, oxycodone, oxycontin, and morphine. The therapies (agonist pharmacotherapy and methadone maintenance) were identified to provide a less harmful opioid (e.g., methadone) or an opioid-receptor agonist (e.g., buprenorphine) under medical supervision in both specialty and outpatient clinics (Krantz & Mehler, 2004; Merrill et al., 2005; World Health Organization [WHO], 2004). Several reviews have identified opioid substitution therapy as effective in reducing illicit opioid use, HIV risk behaviors, criminal activity, and opioid-related death (Connock et al., 2007; WHO, 2004). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Harm reduction is an umbrella term for interventions aiming to reduce the problematic effects of behaviors. Although harm reduction was originally and most frequently associated with substance use, it is increasingly being applied to a multitude of other behavioral disorders. This article reviews the state of empirical research on harm reduction practices including alcohol interventions for youth, college students, and a variety of other adult interventions. We also review nicotine replacement and opioid substitution, as well as needle exchanges and safe injection sites for intravenous drug users. Dozens of peer-reviewed controlled trial publications provide support for the effectiveness of harm reduction for a multitude of clients and disorders without indications of iatrogenic effects. Harm reduction interventions provide additional tools for clinicians working with clients who, for whatever reason, may not be ready, willing, or able to pursue full abstinence as a goal.
    Preview · Article · Feb 2010 · Journal of Clinical Psychology
Show more